SCHEMBL3489110

SCHEMBL3489110

Nc1cc(Cl)cc(Cl)c1S(=O)(=O)NCc1ccc(I)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NR3C1 P04150 5/20 0.40
NR3C2 P08235 5/20 0.40
CA9 Q16790 2/20 0.40
PGR P06401 2/20 0.39
LMNA P02545 1/20 0.39
SLC12A2 P55011 1/20 0.39
SLC12A5 Q9H2X9 1/20 0.39
CYP3A4 P08684 2/20 0.39
CA12 O43570 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
CYP19A1 P11511 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489075 0.92 ALDH1A1 (0.52) ALDH1A1CA1CA2MEN1KMT2A
SCHEMBL3489635 0.88 CYP19A1 (0.43) ALDH1A1CA1CA2MEN1KMT2A
SCHEMBL3488618 0.88 NSD2 (0.50) ALDH1A1CA1CA2MEN1KMT2A
SCHEMBL3488631 0.88 KMT2A (0.52) ALDH1A1MEN1KMT2ANR3C1NR3C2
SCHEMBL3491178 0.87 LMNA (0.52) ALDH1A1CA1CA2MEN1KMT2A
SCHEMBL9275311 0.85 TP53 (0.41) ALDH1A1CA1CA2MEN1KMT2A
SCHEMBL3490432 0.85 CYP19A1 (0.48) MEN1KMT2ANR3C1NR3C2PGR
SCHEMBL3491921 0.85 SMN1; SMN2 (0.53) ALDH1A1KMT2ALMNAL3MBTL1
SCHEMBL9218252 0.84 NSD2 (0.52) ALDH1A1CA1CA2MEN1KMT2A
SCHEMBL3490641 0.84 LMNA (0.52) ALDH1A1LMNACYP19A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D ALDH1A1 2748/4885CA1 4873/4885CA2 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.